Molecular Profile |
Indication/Tumor Type |
Response Type |
Therapy Name |
Approval Status |
Evidence Type |
Efficacy Evidence |
References |
FGFR2 S252W
|
endometrial cancer
|
sensitive |
Debio 1347
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring an FGFR2 S252W mutation in culture and inhibited tumor growth in FGFR2 S252W-positive endometrial cancer cell line xenograft models (PMID: 25169980).
|
25169980
|
FGFR3 Y373C
|
myeloid neoplasm
|
sensitive |
Debio 1347
|
Preclinical |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 Y373C in culture (PMID: 25169980).
|
25169980
|
FGFR3 L608V
|
Advanced Solid Tumor
|
decreased response |
Debio 1347
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells over expressing FGFR3 L608V demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).
|
28034880
|
FGFR2 amp
|
stomach carcinoma
|
sensitive |
Debio 1347
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Debio 1347 inhibited tumor growth in cell line xenograft models of FGFR2 amplified gastric carcinoma (PMID: 26438159).
|
26438159
|
FGFR1 amp
|
lung small cell carcinoma
|
sensitive |
Debio 1347
|
Preclinical |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of small cell lung cancer cell lines harboring FGFR1 amplification in culture (PMID: 25169980).
|
25169980
|
FGFR3 S249C
|
urinary bladder cancer
|
sensitive |
Debio 1347
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of bladder cancer cells harboring FGFR3 S249C in culture and inhibited tumor growth in FGFR3 S249C-positive bladder cancer cell line xenograft models (PMID: 25169980).
|
25169980
|
FGFR2 amp
|
breast cancer
|
sensitive |
Debio 1347
|
Preclinical |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of breast cancer cell lines harboring FGFR2 amplification in culture (PMID: 25169980).
|
25169980
|
ERBB2 amp
|
stomach carcinoma
|
no benefit |
Debio 1347
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of ERBB2 (HER2) amplified gastric carcinoma (PMID: 26438159).
|
26438159
|
FGFR2 amp
|
stomach cancer
|
sensitive |
Debio 1347
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of FGFR-amplified gastric cancer cells in culture and inhibited tumor growth in cell line xenograft models of gastric cancer harboring FGFR2 amplification (PMID: 25169980).
|
25169980
|
FGFR1 amp
|
non-small cell lung carcinoma
|
sensitive |
Debio 1347
|
Preclinical |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of non-small cell lung cancer cell lines harboring FGFR1 amplification in culture (PMID: 25169980).
|
25169980
|
MET amp
|
stomach cancer
|
no benefit |
Debio 1347
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of MET amplified gastric cancer (PMID: 26438159).
|
26438159
|
FGFR2 N549K
|
endometrial cancer
|
sensitive |
Debio 1347
|
Preclinical |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 N549K mutation in culture (PMID: 25169980).
|
25169980
|
FGFR2 V564L
|
Advanced Solid Tumor
|
resistant |
Debio 1347
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Debio 1347 did not inhibit Fgfr2 phosphorylation in transformed cells over expressing FGFR2 V564L in culture (PMID: 25169980).
|
25169980
|
FGFR3-BAIAP2L1
|
urinary bladder cancer
|
sensitive |
Debio 1347
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Debio 1347 decreased phosphorylation of ERK and FRS and inhibited proliferation of a bladder cancer cell line harboring FGFR3-BAIAP2L1 in culture, and inhibited tumor growth in bladder cancer cell line xenograft models with FGFR3-BAIAP2L1 (PMID: 25589496)
|
25589496
|
FGFR3-BAIAP2L1
|
urinary bladder cancer
|
sensitive |
Debio 1347
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of a bladder cancer cell line harboring an FGFR3-BAIAP2L1 fusion in culture (PMID: 25169980).
|
25169980
|
FGFR3 K650E
|
myeloid neoplasm
|
sensitive |
Debio 1347
|
Preclinical |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 K650E in culture (PMID: 25169980).
|
25169980
|
FGFR3 V555M
|
Advanced Solid Tumor
|
decreased response |
Debio 1347
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells over expressing FGFR3 V555M demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).
|
28034880
|
FGFR3 N540K
|
Advanced Solid Tumor
|
decreased response |
Debio 1347
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, transformed cells over expressing FGFR3 N540K demonstrated reduced sensitivity to Debio 1347 in culture (PMID: 28034880).
|
28034880
|
FGFR3 K650E
|
Advanced Solid Tumor
|
sensitive |
Debio 1347
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of transformed cells over expressing FGFR3 K650E in culture (PMID: 28034880).
|
28034880
|
FGFR1 act mut
|
Advanced Solid Tumor
|
sensitive |
Debio 1347
|
Phase I |
Actionable |
In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR1 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).
|
detail...
|
FGFR2 V564F
|
Advanced Solid Tumor
|
sensitive |
Debio 1347
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of transformed cells over expressing FGFR2 V564F in culture and inhibited tumor growth in cell line xenograft models (PMID: 25169980).
|
25169980
|
FGFR2 V564I
|
Advanced Solid Tumor
|
resistant |
Debio 1347
|
Preclinical - Cell culture |
Actionable |
In a preclinical study, Debio 1347 did not inhibit Fgfr2 phosphorylation in transformed cells over expressing FGFR2 V564I in culture (PMID: 25169980).
|
25169980
|
FGFR3 F386L
|
myeloid neoplasm
|
sensitive |
Debio 1347
|
Preclinical |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of myeloma cell lines harboring FGFR3 F386L in culture (PMID: 25169980).
|
25169980
|
FGFR3 act mut
|
Advanced Solid Tumor
|
sensitive |
Debio 1347
|
Phase I |
Actionable |
In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR3 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).
|
detail...
|
FGFR3-TACC3
|
urinary bladder cancer
|
sensitive |
Debio 1347
|
Preclinical - Cell line xenograft |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of bladder cancer cell lines harboring an FGFR3-TACC3 fusion in culture and inhibited tumor growth in FGFR3-TACC3-positive bladder cancer cell line xenograft models (PMID: 25169980).
|
25169980
|
FGFR2 act mut
|
Advanced Solid Tumor
|
sensitive |
Debio 1347
|
Phase I |
Actionable |
In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR2 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).
|
detail...
|
FGFR2 K310R FGFR2 N549K
|
endometrial cancer
|
sensitive |
Debio 1347
|
Preclinical |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of endometrial cancer cells harboring FGFR2 K310R and FGFR2 N549K mutations in culture (PMID: 25169980).
|
25169980
|
FGFR2 amp
|
colorectal cancer
|
sensitive |
Debio 1347
|
Preclinical |
Actionable |
In a preclinical study, Debio 1347 inhibited proliferation of colorectal cancer cell lines harboring FGFR2 amplification in culture (PMID: 25169980).
|
25169980
|